PE20230106A1 - Compuestos de pirimidina fusionados como moduladores de kcc2 - Google Patents
Compuestos de pirimidina fusionados como moduladores de kcc2Info
- Publication number
- PE20230106A1 PE20230106A1 PE2022001943A PE2022001943A PE20230106A1 PE 20230106 A1 PE20230106 A1 PE 20230106A1 PE 2022001943 A PE2022001943 A PE 2022001943A PE 2022001943 A PE2022001943 A PE 2022001943A PE 20230106 A1 PE20230106 A1 PE 20230106A1
- Authority
- PE
- Peru
- Prior art keywords
- kcc2
- modulators
- propan
- pyrimidine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A COMPUESTOS DE PIRIMIDINA FUSIONADOS DE FORMULA (I) DONDE R1, R2, R7 Y EL ANILLO A SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: 2-(DIETILAMINO)-6-(PROPAN-2-IL)-4-{[4-(PROPAN-2-IL)FENIL]AMINO}-5,6-DIHIDRO-7H-PIRROLO[3,4-D]PIRIMIDIN-7-ONA; 4-[(4-CICLOHEXILFENIL)AMINO]-2-(2-CICLOPROPILMORFOLIN-4-IL)-6-(PROPAN-2-IL)-5,6-DIHIDRO-7H-PIRROLO[3,4-D]PIRIMIDIN-7-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL TRANSPORTADOR DE MEMBRANA ELECTRONEUTRO KCC2 SIENDO UTILES EN EL TRATAMIENTO DE EPILEPSIA, DOLOR, TRASTORNOS EL ESPECTRO AUTISTA, COGNICION, ANSIEDAD Y ESCLEROSIS LATERAL AMIOTROFICA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989104P | 2020-03-13 | 2020-03-13 | |
| PCT/EP2021/056393 WO2021180952A1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230106A1 true PE20230106A1 (es) | 2023-01-25 |
Family
ID=74874882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001943A PE20230106A1 (es) | 2020-03-13 | 2021-03-12 | Compuestos de pirimidina fusionados como moduladores de kcc2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230151013A1 (es) |
| EP (1) | EP4103566B1 (es) |
| JP (2) | JP7793529B2 (es) |
| KR (1) | KR20220152319A (es) |
| CN (4) | CN119684299A (es) |
| AU (1) | AU2021234134B2 (es) |
| BR (1) | BR112022018173A2 (es) |
| CA (1) | CA3171192A1 (es) |
| CL (1) | CL2022002386A1 (es) |
| CO (1) | CO2022012884A2 (es) |
| DK (1) | DK4103566T3 (es) |
| ES (1) | ES2962136T3 (es) |
| FI (1) | FI4103566T3 (es) |
| HR (1) | HRP20231314T1 (es) |
| HU (1) | HUE064037T2 (es) |
| IL (1) | IL296265B1 (es) |
| LT (1) | LT4103566T (es) |
| MX (1) | MX2022011354A (es) |
| PE (1) | PE20230106A1 (es) |
| PL (1) | PL4103566T3 (es) |
| PT (1) | PT4103566T (es) |
| RS (1) | RS64823B1 (es) |
| SI (1) | SI4103566T1 (es) |
| SM (1) | SMT202300384T1 (es) |
| WO (1) | WO2021180952A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023107623A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
| US20240109868A1 (en) * | 2022-08-29 | 2024-04-04 | Miracure Biotechnology Limited | Ep300/cbp modulator, preparation method therefor and use thereof |
| AU2024243715A1 (en) * | 2023-04-05 | 2025-10-09 | Axonis Therapeutics, Inc. | Kcc2 potentiators and uses thereof |
| WO2025188952A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies |
| US20250281500A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease |
| US20250281497A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of seizure disorders |
| WO2025188976A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neurodegenerative disorders |
| WO2025188977A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of addiction and insomnia |
| WO2025188974A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics |
| WO2025188973A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes |
| WO2025188955A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders |
| WO2025188953A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| AU2015222865B2 (en) * | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2018217766A1 (en) * | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| JP7399848B2 (ja) * | 2017-09-01 | 2023-12-18 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 |
| EP3801482A4 (en) * | 2018-05-25 | 2022-06-29 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
-
2021
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
- 2021-03-12 US US17/911,051 patent/US20230151013A1/en active Pending
- 2021-03-12 AU AU2021234134A patent/AU2021234134B2/en active Active
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en not_active Ceased
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 SM SM20230384T patent/SMT202300384T1/it unknown
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 CN CN202411881248.3A patent/CN119684299A/zh active Pending
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 CN CN202411881483.0A patent/CN119735594A/zh active Pending
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko active Pending
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 CN CN202411881526.5A patent/CN119684300A/zh active Pending
- 2021-03-12 CN CN202180020856.3A patent/CN115298182B/zh active Active
- 2021-03-12 JP JP2022554784A patent/JP7793529B2/ja active Active
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-06 IL IL296265A patent/IL296265B1/en unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
-
2025
- 2025-09-12 JP JP2025151939A patent/JP2025186368A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230106A1 (es) | Compuestos de pirimidina fusionados como moduladores de kcc2 | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| PE20090729A1 (es) | Moduladores de gamma-secretasa | |
| MA59373B1 (fr) | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 | |
| PE20221628A1 (es) | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos | |
| PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
| PE20110833A1 (es) | Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20201185A1 (es) | Inhibidores de la oxacina monoacilglicerol lipasa (magl) | |
| PE20211733A1 (es) | Amidas de pirrolidina sustituidas | |
| PE20070712A1 (es) | Sulfonamidas biciclicas como moduladores del receptor de glucocorticoides en el tratamiento de enfermedades inflamatorias | |
| PE20212089A1 (es) | Compuestos utiles en la terapia del vih | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| PE20120413A1 (es) | ENANTIOMERO (S) DE 1'-{[5-(TRIFLUOROMETIL)FURAN-2-IL]METIL}ESPIRO[FURO[2,3-f][1,3]BENZODIOXOL-7,3'-INDOL]-2'(1'H)-ONA | |
| PE20090160A1 (es) | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA | |
| CO6551729A2 (es) | Moduladores alostericos positivos de receptores de m1 de quinolina amida | |
| SV2002000696A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos pc9985ahxk/bb | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| PE20080730A1 (es) | Derivados de fenilo como moduladores del receptor s1p | |
| PE20090957A1 (es) | Moduladores de gamma secretasa | |
| PE20220710A1 (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl) | |
| DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. |